Bottom line
Is THISX a good fund? The bottom line
THISX is the T. Rowe Price Health Sciences Fund-I Class share class of T. Rowe Price Health Sciences Fund, Inc., an actively managed health care sector mutual fund from T. Rowe Price.
Its expense ratio is 0.68% — about $68 a year on every $10,000 invested, cheaper than 70% of health care sector funds we track.
It returned +17.9% over one year, +4.3% a year over five years (as of Dec 31, 2025, per its prospectus).
With $11.9 billion in net assets and 279 holdings, its largest position is Eli Lilly & Co (14.3%) and the top 10 make up 47.6% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 80% top-holdings overlap).
What stands out
- Broadly diversified (279 holdings)
- Large and established ($11.9 billion)
Updated Nov 19, 2026
What THISX invests in
The fund seeks long-term capital appreciation.
In the Summary Prospectus, and Sections 1 and 2 of the Prospectus, the disclosure under Principal Investment Strategies is supplemented as follows: The fund is nondiversified, which means it may invest a greater percentage of its assets in a particular issuer than is permissible for a diversified fund.
From the fund's prospectus (filed Jun 30, 2026).
THISX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| THISX | +17.9% | +4.3% | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What THISX costs
On a $10,000 investment, THISX's 0.68% expense ratio costs about $68 a year. The prospectus estimates $847 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
THISX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 14.28% |
| 2 | Johnson & Johnson | 6.63% |
| 3 | Unitedhealth Group Inc | 5.99% |
| 4 | Abbvie Inc | 5.10% |
| 5 | Merck & Co. Inc. | 4.01% |
| 6 | Gilead Sciences Inc | 2.82% |
| 7 | Thermo Fisher Scientific Inc | 2.52% |
| 8 | Vertex Pharmaceuticals Inc | 2.28% |
| 9 | Bristol-myers Squibb Co | 2.11% |
| 10 | Abbott Laboratories | 1.89% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 47.6% of the fund. See all top 25 holdings and asset mix →
Alternatives to THISX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 80% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 78% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 79% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 77% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 58% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 73% | Compare |